You need to sign in or sign up before continuing.
Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · Nov 2003
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
Hemophilia A patients with inhibitors are generally treated with preparations containing activated coagulation factors to achieve hemostasis by bypassing factor (F)VIII. ⋯ This assay enables the pharmacodynamic and pharmacokinetic properties of bypassing therapies to be monitored, thus helping to optimize treatment.